SEW​2871

SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC₅₀ of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses^[1][2]. IC50 & Target: EC50: 13.8 nM (S1P1)^[2] In Vitro: SEW2871 exerts a powerful migratory effect by increasing smooth muscle α-actin, procollagen αI and αIII, and total hydroxyproline contents in LX-2 cells (a human hepatic stellate cell line)^[2]. In Vivo: SEW2871 (20 mg/kg, Gavage, once daily for 2 weeks) ameliorates established experimental colitis in IL-10^–/– mice^[3].
SEW2871 (0.5 mg/kg, IP, daily for 2 weeks) inhibited β amyloid (Aβ_1-42)-induced spatial memory impairment and hippocampal neuronal loss in a rat model of Alzheimer’s disease^[2].
SEW2871 (0-0.3 mg/kg, IV) attenuates LPS-induced acute inflammatory lung injury, produces dose-dependent alveolar and vascular barrier protection in C57Bl/6 mice^[2].
SEW2871 is effective in protecting kidneys against ischaemia-reperfusion injury by reducing CD4⁺ T cell infiltration in mice^[3].